Pulmonary hypertension (PH) is a severe, progressive vascular disorder characterized by elevation in pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR), finally leading to right heart failure and death. During the rise in PAP and PVR, vascular remodeling is accompanied by accumulation of pulmonary artery smooth muscle cells (PASMCs), endothelial cells (ECs), fibroblasts, myofibroblasts and pericytes in pulmonary arterial wall, which leads to thickening of the inner and outer linings of blood vessels, loss and obstructive remodeling of the pulmonary vascular bed and perivascular inflammation. 1-3 Associated with multiple primary causes, PH encompasses a group of clinical entities. According to the latest classification proposed by the Sixth World Symposium on PH, the disease can develop due to pulmonary arterial disorder, left heart disease, lung disease or hypoxia, chronic thromboembolic disease and other unclear or multifactorial mechanisms. 4 Though current treatments can improve clinical symptoms and hemodynamic abnormality to some extent, it is difficult to target pulmonary vascular remodeling and
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.